Payment Models and Practice Changes: Meeting Requirements of OCM & MACRA
By clicking the continue button above, I certify I have read the CME/CE information below.
Payment Models and Practice Changes: Meeting Requirements of OCM & MACRA
Release Date: January 24, 2018
Expiration Date: January 24, 2019
Recent legislation and policy has fast-tracked the shift of healthcare payment from volume- to value-based reimbursement under the Medicare Access and CHIP Reauthorization Act (MACRA) for oncology care. Today, oncologists have the option to be reimbursed for Medicare patients under the CMS Oncology Care Model (OCM), an alternative payment model spanning a 6-month chemotherapy episode-of-care. This activity will provide insight into the program’s structure and challenges. It will also review new provider models and use of data systems to improve cancer care delivery.
The primary audiences for this activity are:
- Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
- Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
- Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
- Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)
Therese Marie Mulvey, MD
Director of Quality Safety and Value
Massachusetts General Hospital Cancer Center
Director Breast Oncology
MGH/North Shore Cancer Center
Therese Marie Mulvey, MD, FASCO is the Director of Breast Oncology at the Massachusetts General Hospital North Shore Cancer Center in Danvers, MA and the Director of Quality Safety and Value for the MGH Cancer Center and Network Affiliates. She was previously Physician-in-Chief at Southcoast Centers for Cancer Care in New Bedford, MA. Dr. Mulvey previously worked as a physician at other community practices in Massachusetts, including East Boston Neighborhood Health Center and Commonwealth Hematology Oncology, where she also served as President and Chief Executive Officer. She is an Assistant Professor at Tufts Medical School.
Dr. Mulvey has served as Chair of the Clinical Practice Committee and on the Editorial Board of the Journal of Oncology Practice. She has served as Chair of the Oncology Carrier Advisory Committee, and recently served on the Board of Directors of ASCO. Dr. Mulvey has served on the Quality of Care Committee, Value in Cancer Care Task Force, State Affiliate Council, Cancer Education Committee, and Best of ASCO Planning Committee. She received her medical degree from Tufts University School of Medicine, and completed her internship, residency, and fellowship at New England Medical Center. She completed a research and clinical fellowship at Massachusetts General Hospital.
Charles Saunders, MD
Chief Executive Officer
West Palm Beach, FL
Charles Saunders, MD is Chief Executive Officer at Integra Connect. Dr. Saunders is a physician executive who combines a clinical, business, and technology background. He was formerly CEO of Healthagen (an Aetna company) which provides population health technology and services. He has previously held other leadership roles, including as CEO of Broadlane, a large GPO and supply chain technology company; President of EDS Healthcare Global Industry Group; and CMO of Healtheon/WebMD. As an emergency physician, he headed the EMS Services in the City of San Francisco. Dr. Saunders received his medical doctorate from Johns Hopkins University and a bachelor’s in biology from University of Southern California.
At the conclusion of this session, participants should be able to demonstrate the ability to:
- Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
- Understand the development of quality measures as a component of new payment models
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits TM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.
Total number of CE credits made available is 1.50 hours (0.15 CEUs).
A statement of credit will be issued only upon receipt of a completed activity evaluation.
This is an application-based activity.
For questions regarding CME/CE credit, the post-test, evaluation, please email email@example.com.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.6 contact hours.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Therese Marie Mulvey, MD: Nothing to disclose
Charles Saunders, MD: CEO of Integra Connect
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose
Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene
Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 66% or better, and evaluation. The estimated time for completion of this activity is 1.5 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the posttest. Participant is allowed to take the posttest multiple times.
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.